Aeolus Pharmaceuticl (AOLS) 0.2500 $AOLS
Tetraphase Pharmaceuticals (TTPH) in Focus: Stock Up 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:32AM CDT
Tetraphase Pharmaceuticals, (TTPH) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Global Malignant Mesothelioma Therapeutics Pipeline Review 2014 - 11 Companies & 25 Companies
M2 - Fri Sep 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qjk7h/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals Inc. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - BNC-105 - FPI-01 - YS-110 - BIW-8962 - Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - ONCOS-102 - Drug For Mesothelioma - Oshadi D Oshadi R - AEOL-10150 - anetumab ravtansine - LY-3023414 - Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - VS-4718 - VS-5584 - BERTA - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Ad5-SGE-REIC/Dkk3 Gene Therapy - pemetrexed disodium - Vaccine For Cancer - YP-223 - YYP-218 - YP-3 - DP-3975 - Tb-535C - SentoClone For more information visit http://www.researchandmarkets.com/research/8qjk7h/malignant
Aeolus Announces Positive Results From Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
Marketwire - Thu Sep 04, 6:02AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced results from a large study in non-human primates (NHPs) demonstrating that 60 days of treatment with AEOL 10150 improved survival from 25 percent to 50 percent -- doubling survival at 180 days after radiation exposure to the lungs. The survival data was presented at an In Process Review ("IPR"
meeting with the Biomedical Advanced Research and Development Authority ("BARDA" yesterday. The study results will be included in a pre-Emergency Use Authorization ("EUA" submission to the FDA.
Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
Marketwire - Wed Aug 20, 12:00PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of Medical Imaging Products of the US Food and Drug Administration (FDA) to enable the initiation of a phase 1 study of AEOL 10150 in healthy human volunteers. The new phase 1 study is designed as the first step in meeting the requirements for approval of the drug as a medical countermeasure for lung damage due to radiation exposure (Lung-ARS) under the FDA's "Animal Rule." Aeolus is developing AEOL 10150 for this indication under a five-year contract with the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $118 million.
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
Marketwire - Fri Aug 15, 6:02AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three and nine months ended June 30, 2014.
Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.
Jazz Pharmaceuticals Public Limited Company (JAZZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:32AM CDT
Jazz Pharmaceuticals Public Limited Company (JAZZ) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 7:51AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.
Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:46AM CDT
Tesaro (TSRO) was a big mover last session, with shares rising nearly 9% on the day.
Salix Pharmaceuticals (SLXP) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:51AM CDT
Salix Pharmaceuticals Ltd. (SLXP) was a big mover last session, as its shares rose over 11% on the day.
IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.
Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 7:59AM CDT
Auxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard Gas
Marketwire - Tue Jul 01, 6:30AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
QLT Inc. (QLTI) in Focus: Stock Surges 14.63% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 7:44AM CDT
QLT Inc. (QLTI) was a big mover last session, as the company saw its shares rally nearly 15% on the day.
Heron Therapeutics (HRTX) in Focus: Stock Falls 8.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:51AM CDT
Heron Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell almost 9% on the day.
Cardiome Pharma (CRME) Jumps: Stock Gains 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:46AM CDT
Cardiome Pharma (CRME) was a big mover last session, with shares rising over 7% on the day.
Genocea Biosciences (GNCA) Jumps: Stock Rises 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:39AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as its shares rose nearly 9% on the day.
Heron Therapeutics (HRTX) in Focus: Stock Gains 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:25AM CDT
Heron Therapeutics (HRTX) was a big mover last session, with shares rising over 7% on the day.
Weakness Seen in Cerulean Pharma (CERU): Stock Slumps 20.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:57AM CDT
Cerulean Pharma has seen negative earnings estimate revision for the current quarter along with a significant decline in its share price for the last day
Flamel Technologies (FLML) Jumps: Stock Adds 18.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:51AM CDT
Flamel Technologies SA (FLML) was a big mover last session, as its shares rose nearly 19% on the day.
Tetraphase Pharmaceuticals (TTPH) in Focus: Stock Up 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:32AM CDT
Tetraphase Pharmaceuticals, (TTPH) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Global Malignant Mesothelioma Therapeutics Pipeline Review 2014 - 11 Companies & 25 Companies
M2 - Fri Sep 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qjk7h/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals Inc. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - BNC-105 - FPI-01 - YS-110 - BIW-8962 - Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - ONCOS-102 - Drug For Mesothelioma - Oshadi D Oshadi R - AEOL-10150 - anetumab ravtansine - LY-3023414 - Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - VS-4718 - VS-5584 - BERTA - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Ad5-SGE-REIC/Dkk3 Gene Therapy - pemetrexed disodium - Vaccine For Cancer - YP-223 - YYP-218 - YP-3 - DP-3975 - Tb-535C - SentoClone For more information visit http://www.researchandmarkets.com/research/8qjk7h/malignant
Aeolus Announces Positive Results From Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
Marketwire - Thu Sep 04, 6:02AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced results from a large study in non-human primates (NHPs) demonstrating that 60 days of treatment with AEOL 10150 improved survival from 25 percent to 50 percent -- doubling survival at 180 days after radiation exposure to the lungs. The survival data was presented at an In Process Review ("IPR"
meeting with the Biomedical Advanced Research and Development Authority ("BARDA" yesterday. The study results will be included in a pre-Emergency Use Authorization ("EUA" submission to the FDA. Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
Marketwire - Wed Aug 20, 12:00PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of Medical Imaging Products of the US Food and Drug Administration (FDA) to enable the initiation of a phase 1 study of AEOL 10150 in healthy human volunteers. The new phase 1 study is designed as the first step in meeting the requirements for approval of the drug as a medical countermeasure for lung damage due to radiation exposure (Lung-ARS) under the FDA's "Animal Rule." Aeolus is developing AEOL 10150 for this indication under a five-year contract with the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $118 million.
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
Marketwire - Fri Aug 15, 6:02AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three and nine months ended June 30, 2014.
Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.
Jazz Pharmaceuticals Public Limited Company (JAZZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:32AM CDT
Jazz Pharmaceuticals Public Limited Company (JAZZ) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 7:51AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.
Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:46AM CDT
Tesaro (TSRO) was a big mover last session, with shares rising nearly 9% on the day.
Salix Pharmaceuticals (SLXP) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:51AM CDT
Salix Pharmaceuticals Ltd. (SLXP) was a big mover last session, as its shares rose over 11% on the day.
IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.
Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 7:59AM CDT
Auxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard Gas
Marketwire - Tue Jul 01, 6:30AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
QLT Inc. (QLTI) in Focus: Stock Surges 14.63% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 7:44AM CDT
QLT Inc. (QLTI) was a big mover last session, as the company saw its shares rally nearly 15% on the day.
Heron Therapeutics (HRTX) in Focus: Stock Falls 8.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:51AM CDT
Heron Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell almost 9% on the day.
Cardiome Pharma (CRME) Jumps: Stock Gains 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:46AM CDT
Cardiome Pharma (CRME) was a big mover last session, with shares rising over 7% on the day.
Genocea Biosciences (GNCA) Jumps: Stock Rises 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:39AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as its shares rose nearly 9% on the day.
Heron Therapeutics (HRTX) in Focus: Stock Gains 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:25AM CDT
Heron Therapeutics (HRTX) was a big mover last session, with shares rising over 7% on the day.
Weakness Seen in Cerulean Pharma (CERU): Stock Slumps 20.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:57AM CDT
Cerulean Pharma has seen negative earnings estimate revision for the current quarter along with a significant decline in its share price for the last day
Flamel Technologies (FLML) Jumps: Stock Adds 18.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:51AM CDT
Flamel Technologies SA (FLML) was a big mover last session, as its shares rose nearly 19% on the day.
